At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 54 enrolled
Drug / intervention
lipoic acid +1 moredrug
Likely dose
lipoic acid 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Lipoic Acid for Neuroprotection in Secondary Progressive MS
In Brief
A Phase 3 clinical trial evaluating lipoic acid and Placebo for Multiple Sclerosis, Chronic Progressive. Completed, enrolled 54 participants across 1 site.
Detailed Summary
The purpose of the study is to determine if lipoic acid can protect the brain and slow disability in secondary progressive multiple sclerosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Chronic Progressive
CountriesUnited States
CollaboratorsOregon Health and Science University
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartOct 2010
Primary CompletionAug 2015
TodayJul 2026
First PostedAug 26, 2010
Enrollment StartOct 1, 2010
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 15.8 years ago
Interventions
lipoic aciddrug
1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.
Placebodrug
The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation